Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 3/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.39 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.39 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | RAPGEF4 | Q8WZA2 | 4/20 | 0.35 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1936771 | 1.00 | MEN1 (0.43) | MEN1KMT2AMAPK1MAPTSMN1; SMN2 | |
| SCHEMBL187717 | 1.00 | MEN1 (0.43) | MEN1KMT2AMAPK1MAPTSMN1; SMN2 | |
| SCHEMBL20094268 | 0.88 | MEN1 (0.33) | MEN1KMT2AMAPK1MAPTSMN1; SMN2 | |
| SCHEMBL3976134 | 0.82 | F2 (0.44) | MEN1KMT2AMAPK1MAPTSMN1; SMN2 | |
| SCHEMBL25843755 | 0.81 | MEN1 (0.40) | MEN1KMT2AMAPK1MAPTSMN1; SMN2 | |
| SCHEMBL20638381 | 0.80 | MEN1 (0.39) | MEN1KMT2AMAPK1MAPTSMN1; SMN2 | |
| SCHEMBL29488823 | 0.77 | F2 (0.38) | MEN1KMT2AMAPK1MAPTSMN1; SMN2 | |
| SCHEMBL16906381 | 0.76 | KMT2A (0.43) | MEN1KMT2AMAPK1MAPTSMN1; SMN2 | |
| SCHEMBL12334874 | 0.76 | KMT2A (0.43) | MEN1KMT2AMAPK1MAPTSMN1; SMN2 | |
| SCHEMBL5075060 | 0.72 | MEN1 (0.44) | MEN1KMT2AMAPK1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 185 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731207-A2 | INHIBITORS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS AND METAPNEUMOVIRUS | Merck Sharp & Dohme LLC (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-4384523-B1 | 2,2-DIFLUORO-5H-[1,3]DIOXOLO[4,5-F]ISOINDOL-7-ONE DERIVATIVES AS PESTICIDES | SYNGENTA CROP PROTECTION AG (CH) | 2026-04-08 | — | — | EP | disclosed |
| EP-4698517-A1 | <SUP2/>? <SUB2/>?4?NOVEL COMPOUNDS AS ?? <NS1:SUB>7</NS1:SUB>?INHIBITORS | Evotec International GmbH (DE) | 2026-02-25 | — | — | EP | disclosed |
| US-20260049061-A1 | SMALL MOLECULES AS KCNQ2/3 (KV7.2/3) CHANNEL ACTIVATORS AND THEIR MEDICAL USE THEREOF | YICHANG HUMANWELL PHARMACEUTICALS CO., LTD. (CN) | 2026-02-19 | — | — | US | disclosed |
| US-12503471-B2 | Triazatricycle compounds for the treatment of autoimmune disease | HOFFMANN-LA ROCHE INC. (US) | 2025-12-23 | — | — | US | disclosed |
| US-12421240-B2 | Hydropyrazino[1,2-d][1,4]diazepine compounds for the treatment of autoimmune disease | HOFFMANN-LA ROCHE INC. (US) | 2025-09-23 | — | — | US | disclosed |
| EP-4615838-A1 | SUBSTITUTED BI-AND TRICYCLIC HSET INHIBITORS | Merck Patent GmbH (DE) | 2025-09-17 | — | — | EP | disclosed |
| US-20250262201-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | AGIOS PHARMACEUTICALS, INC. | 2025-08-21 | — | — | US | disclosed |
| US-12331046-B2 | CTPS1 inhibitors and uses thereof | NIMBUS CLOTHO, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| US-20250171438-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | AGIOS PHARMACEUTICALS, INC. | 2025-05-29 | — | — | US | disclosed |
| US-20110003807-A1 | Thiazole derivatives | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-20110003806-A1 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-20100184800-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2010-07-22 | — | — | US | disclosed |
| WO-2010069322-A1 | TRIAZOLOPYRIDINES AS PHOSPHODIESTERASE INHIBITORS FOR TREATMENT OF DERMAL DISEASES | LEO PHARMA A/S (DK) | 2010-06-24 | — | — | WO | disclosed |
| WO-2010030538-A2 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-03-18 | — | — | WO | disclosed |
| US-20100063068-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2010-03-11 | — | — | US | disclosed |
| WO-2009147414-A1 | OLEFIN METATHESIS REACTIONS OF AMINO ACIDS, PEPTIDES AND PROTEINS CONTAINING ALLYL SULFIDE GROUPS | ISIS INNOVATION LIMITED (GB) | 2009-12-10 | — | — | WO | disclosed |
| US-20090143592-A1 | Glucagon Antagonists/Inverse Agonists | NOVO NORDISK A/S (DK) | 2009-06-04 | — | — | US | disclosed |
| US-20090143592-A1 | Glucagon Antagonists/Inverse Agonists | NOVO NORDISK A/S (DK) | 2009-06-04 | — | — | US | disclosed |
| WO-2000069810-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2000-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12421240-B2 | Hydropyrazino[1,2-d][1,4]diazepine compounds for the treatment of autoimmune disease | HRH3, HRH4, HRH2 | MEN1 121/4885KMT2A 843/4885MAPK1 825/4885 |
| US-20250262201-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | PAH, KDM8, PHF8 | MEN1 3131/4885KMT2A 40/4885MAPK1 1588/4885 |
| US-20100063068-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | MEN1 4795/4885KMT2A 4722/4885MAPK1 2985/4885 |
| US-20260049061-A1 | SMALL MOLECULES AS KCNQ2/3 (KV7.2/3) CHANNEL ACTIVATORS AND THEIR MEDICAL USE THEREOF | KCNN3, KCNA7, KCNQ3 | MEN1 2392/4885KMT2A 484/4885MAPK1 1497/4885 |
| US-20100184800-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | MEN1 4795/4885KMT2A 4722/4885MAPK1 2985/4885 |
| US-20110003807-A1 | Thiazole derivatives | MTOR, RICTOR, AKT2 | MEN1 794/4885KMT2A 2441/4885MAPK1 38/4885 |
| US-20090143592-A1 | Glucagon Antagonists/Inverse Agonists | GLP1R, GPR119, GCGR | MEN1 2079/4885KMT2A 3304/4885MAPK1 380/4885 |
| US-20110003806-A1 | Heteroaryls and uses thereof | RICTOR, MTOR, AKT1S1 | MEN1 1649/4885KMT2A 2459/4885MAPK1 102/4885 |
| US-12331046-B2 | CTPS1 inhibitors and uses thereof | CTPS1, CTPS2, ECHS1 | MEN1 4328/4885KMT2A 3259/4885MAPK1 4157/4885 |
| US-12503471-B2 | Triazatricycle compounds for the treatment of autoimmune disease | SSB, HLA-DRB1, PKD1 | MEN1 115/4885KMT2A 1065/4885MAPK1 2018/4885 |
| US-20250171438-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | PAH, KDM8, PHF8 | MEN1 3131/4885KMT2A 40/4885MAPK1 1588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.